Video
Faricimab for DME: Results of phase 3 YOSEMITE and RHINE trials
Author(s):
Caroline Baumal, MD, highlights results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in DME.
Ophthalmology Times®' Sheryl Stevenson speaks with Caroline Baumal, MD, professor of ophthalmology, Tufts University School of Medicine; New England Eye Center (Boston, MA), on results from the Phase 3 YOSEMITE and RHINE trials, providing an overview of the efficacy, safety and durability of faricimab in diabetic macular edema (DME).
---
The American Society of Retina Specialists (ASRS) is hosting its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
